Developing Novel Protein Degradation Inhibitors for the Treatment of Cancer

Building upon the long-standing observation of tumor regression in the setting of bacterial infection, we have developed a unique and patented approach designed to exploit bacteria’s natural ability to fully engage the human immune system and cure disease. Our novel insights have enabled us to create proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models to date.